M Colombo

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi Treatment of chronic hepatitis C in Europe
    Massimo Colombo
    Division of Hepatology, IRCCS Maggiore Hospital, Department of Medicine, University of Milan, Via Pace 9, 20122 Milan, Italy
    J Hepatobiliary Pancreat Surg 10:168-71. 2003
  2. ncbi Natural history of hepatocellular carcinoma
    Massimo Colombo
    Department of Gastroenterology and Endocrinology, A M and A Migliavacca Center for Liver Disease, IRCCS, Maggiore Hospital, University of Milan, Milan, Italy
    Cancer Imaging 5:85-8. 2005
  3. ncbi Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
    Pietro Lampertico
    1st Gastroenterology Unit, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Via F Sforza 35 20122 Milan, Italy
    Gut 62:290-8. 2013
  4. ncbi The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma
    Massimo Iavarone
    A M and A Migliavacca Center, Division of Hepatology and FIRC Liver Cancer Unit, IRCCS Maggiore Policlinico Hospital, University of Milan, Milan, Italy
    Cancer 98:529-34. 2003
  5. ncbi How I manage my patients with hepatocellular carcinoma
    Massimo Colombo
    Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Liver Int 31:145-50. 2011
  6. ncbi The European approach to hepatocellular carcinoma
    Massimo Colombo
    Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    Hepatogastroenterology 49:12-6. 2002
  7. ncbi Natural history of hepatocellular carcinoma
    Massimo Colombo
    Department of Medicine, A M and A Migliavacca Center for Liver Disease, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena and University of Milan, Milan, Italy
    Ann Ital Chir 79:91-7. 2008
  8. ncbi Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons
    Massimo Colombo
    First Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Dig Liver Dis 42:S298-301. 2010
  9. ncbi Screening and diagnosis of hepatocellular carcinoma
    Massimo Colombo
    A M and A Migliavacca Center for Liver Diseases, 1st Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Liver Int 29:143-7. 2009
  10. ncbi Etiology, natural history and treatment of hepatocellular carcinoma
    Massimo Colombo
    IRCCS Maggiore Hospital, Fondazione Italiana Ricerca Cancro Unit of Liver Cancer, University of Milan, Via Pace 9, 20122 Milan, Italy
    Antiviral Res 60:145-50. 2003

Detail Information

Publications108 found, 100 shown here

  1. ncbi Treatment of chronic hepatitis C in Europe
    Massimo Colombo
    Division of Hepatology, IRCCS Maggiore Hospital, Department of Medicine, University of Milan, Via Pace 9, 20122 Milan, Italy
    J Hepatobiliary Pancreat Surg 10:168-71. 2003
    ..Extended treatment of the latter patients with pegylated interferon might slow down the progression of fibrosis...
  2. ncbi Natural history of hepatocellular carcinoma
    Massimo Colombo
    Department of Gastroenterology and Endocrinology, A M and A Migliavacca Center for Liver Disease, IRCCS, Maggiore Hospital, University of Milan, Milan, Italy
    Cancer Imaging 5:85-8. 2005
    ..Prognostication of patients with hepatocellular carcinoma takes into account the size and number of tumor nodes and their relation to the portal veins, and the degree of liver impairment...
  3. ncbi Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
    Pietro Lampertico
    1st Gastroenterology Unit, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Via F Sforza 35 20122 Milan, Italy
    Gut 62:290-8. 2013
    ..A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population...
  4. ncbi The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma
    Massimo Iavarone
    A M and A Migliavacca Center, Division of Hepatology and FIRC Liver Cancer Unit, IRCCS Maggiore Policlinico Hospital, University of Milan, Milan, Italy
    Cancer 98:529-34. 2003
    ..Recently, another estrogen receptor (ERbeta) has been identified, but its relevance in liver diseases is unknown...
  5. ncbi How I manage my patients with hepatocellular carcinoma
    Massimo Colombo
    Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Liver Int 31:145-50. 2011
    ..While the prognosis is still poor in patients with advanced HCC, the recent availability of multikinase inhibitors has generated hope for improving survival in these patients...
  6. ncbi The European approach to hepatocellular carcinoma
    Massimo Colombo
    Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    Hepatogastroenterology 49:12-6. 2002
    ..Being curative treatments applicable only to patients with a small tumor, hepatocellular carcinoma surveillance aimed at early detection of the tumor is the most practical approach for improving treatment outcome...
  7. ncbi Natural history of hepatocellular carcinoma
    Massimo Colombo
    Department of Medicine, A M and A Migliavacca Center for Liver Disease, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena and University of Milan, Milan, Italy
    Ann Ital Chir 79:91-7. 2008
    ..However, ageing of the patients, deterioration of liver function during surveillance, occurrence of multinodular tumors and limited access to liver transplantation may hamper surveillance programs effectiveness...
  8. ncbi Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons
    Massimo Colombo
    First Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Dig Liver Dis 42:S298-301. 2010
    ..Finally, tertiary prevention with anti-HBV treatments is controversial, due to the existence of a few, methodologically flawed studies...
  9. ncbi Screening and diagnosis of hepatocellular carcinoma
    Massimo Colombo
    A M and A Migliavacca Center for Liver Diseases, 1st Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Liver Int 29:143-7. 2009
    ..The cost-effectiveness ratio of surveillance depends on multiple factors, like HCC incidence, the cost and accuracy of diagnostic tests and the costs and outcome of the therapeutic interventions...
  10. ncbi Etiology, natural history and treatment of hepatocellular carcinoma
    Massimo Colombo
    IRCCS Maggiore Hospital, Fondazione Italiana Ricerca Cancro Unit of Liver Cancer, University of Milan, Via Pace 9, 20122 Milan, Italy
    Antiviral Res 60:145-50. 2003
    ..Whether arterial chemoembolization benefits patients with HCC remains controversial...
  11. ncbi Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation
    Massimo Iavarone
    1st Division of Gastroenterology, Center for Liver Diseases, Milan, Italy
    Hepatology 52:1723-30. 2010
    ..006). CONCLUSION: Tumor grade, a relevant predictor of disease severity, influences the accuracy of dynamic contrast techniques in the diagnosis of HCC...
  12. ncbi Prevention of hepatocellular carcinoma
    Massimo Colombo
    Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital, University of Milan, 20122 Milan, Italy
    Semin Liver Dis 25:155-61. 2005
    ..Dietary interventions and antiaflatoxin agents might help to prevent HCC in susceptible individuals, but the real efficacy of these approaches is far from being demonstrated...
  13. ncbi Treatment of hepatocellular carcinoma
    M Colombo
    Department of Hepatology, IRCCS Maggiore Hospital, University of Milan, Via Pace No 9, 20122 Milan, Italy
    Antiviral Res 52:209-15. 2001
    ..The 5-year survival is approximately 50% but it copes with a high risk of tumor recurrence. Patients with advanced tumor disease cannot be offered curative treatments but only symptomatic treatments...
  14. ncbi Nonpercutaneous therapies of hepatocellular carcinoma
    M Colombo
    Division of Internal Medicine and Fondazione Italiana Ricerca Cancro FIRC Center on Liver Tumors, A M and A Migliavacca Center for Liver Diseases, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
    Hepatogastroenterology 48:25-8. 2001
    ..Conventional radiotherapy with external irradiation was not effective against hepatocellular carcinoma...
  15. ncbi Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation
    M Vigano
    I Gastroenterology Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Aliment Pharmacol Ther 34:353-62. 2011
    ..Transient elastography has gained popularity to stage liver fibrosis in chronic viral hepatitis, however, diagnostic cut-offs for severe fibrosis in chronic hepatitis B are poorly defined...
  16. ncbi High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity
    M F Donato
    Division of Hepatology, IRCCS Maggiore Hospital, Milan, Italy
    Hepatology 34:523-8. 2001
    ..75%; P <.0001). In conclusion, development of HCC in patients with compensated cirrhosis seems to be reliably predicted by liver cell proliferation status...
  17. ncbi Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy
    M E Mancuso
    Department of Medicine and Medical Specialities, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 7:1997-2005. 2009
    ..OBJECTIVES AND PATIENTS: In this open-label, prospective, multicenter study, the efficacy and safety of therapy with Peg-IFNalpha2a plus Rbv was evaluated in 34 HCV/HIV-coinfected adult hemophiliacs naive to previous antiviral therapy...
  18. ncbi High prevalence but low pathogenicity of hepatitis G virus infection in Italian patients with genetic haemochromatosis
    F De Filippi
    Angela Maria e Antonio Migliavacca Centre for Liver Disease, Department of Internal Medicine, University of Milan, Italy
    Ital J Gastroenterol Hepatol 30:529-33. 1998
    ..Various environmental factors have been shown to hasten cirrhosis and hepatocellular carcinoma in patients with genetic haemochromatosis...
  19. ncbi Hepatitis C in haemophilia: lights and shadows
    M G Rumi
    Department of Gastroenterology and Endocrinology, A. Bianchi Bonomi Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, 20122 Milan, Italy
    Haemophilia 10:211-5. 2004
    ..The development of newer interferon-based therapies provides an opportunity for modifying the natural history of HCV infection in a substantial number of haemophilic patients...
  20. ncbi The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype
    Alessio Aghemo
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 14:577-84. 2009
    ..We aimed to assess whether cirrhosis modifies the pattern of PEG-IFN-alpha2b and RBV treatment failure...
  21. ncbi Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation
    C Rigamonti
    First Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Sforza, 35 20122 Milano, Italy
    Gut 57:821-7. 2008
    ..This procedure, however, warrants further validation in the setting of liver transplantation (LT), including patients under follow-up for recurrent hepatitis C...
  22. ncbi Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma
    M Iavarone
    AM and A Migliavacca Center for Liver Diseases, Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    J Viral Hepat 14:133-9. 2007
    ..There was a gradient of VEGF-165 between hepatic and femoral veins in both HCC and cirrhosis. In conclusion, VEGF appears to be involved in the development of HCC and it could be a predictor of HCC development in patients with cirrhosis...
  23. ncbi Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients
    E Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    Transfusion 44:790-4. 2004
    ..35%). CONCLUSIONS: High-dose IFN therapy plus ribavirin provided high rates of sustained virologic responses in adult hemophiliacs with chronic HCV, even if side-effects led to dose reduction in half of these patients...
  24. ncbi Polytherapy in bone regeneration: clinical applications and preliminary considerations
    G M Calori
    C O R, Orthopaedic Institute, G Pini, University of Milan, Italy
    Int J Immunopathol Pharmacol 24:85-90. 2011
    ..Polytherapy seems to be a logical option to improve the healing rate, nevertheless, there are not still extensive studies that validate this strategy and moreover, some questions are not resolved...
  25. ncbi Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients
    M G Rumi
    AM and A Migliavacca Centre for the Study of Liver Disease and Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Gut 54:402-6. 2005
    ....
  26. ncbi Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin
    L Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Aliment Pharmacol Ther 35:1434-42. 2012
    ..Homozygosity for the PNPLA3 p.I148M polymorphism influences steatosis and fibrogenesis in chronic hepatitis C (CHC)...
  27. ncbi Serum autoantibodies against cytochrome P450 2E1 (CYP2E1) predict severity of necroinflammation of recurrent hepatitis C
    C Rigamonti
    First Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena and University of Milan, Italy
    Am J Transplant 9:601-9. 2009
    ..We propose that autoimmune reactions involving CYP2E1 might contribute to hepatic damage in a subgroup of transplanted patients with recurrent hepatitis C...
  28. ncbi Chromogranin A levels in chronic liver disease and hepatocellular carcinoma
    S Massironi
    Gastroenterology Unit II, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Dig Liver Dis 41:31-5. 2009
    ..Hepatocellular carcinoma (HCC) is the relevant cause of death in patients with compensated cirrhosis. Alpha-fetoprotein (AFP) is used for screening HCC, with limited success...
  29. ncbi Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine
    M Vigano
    A M and A Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    J Viral Hepat 15:922-4. 2008
    ..These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response...
  30. ncbi Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy
    Roberta Soffredini
    A.M. Migliavacca Center for Liver Disease, Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital and University of Milan, Via Pace 9, 20122 Milan, Italy
    Am J Gastroenterol 99:1738-43. 2004
    ..CONCLUSIONS: In conclusion, the HCV core antigen is a less sensitive test of HCV viremia than HCV-RNA assays and is competitive with the bDNA assay as an early predictor of a nonresponse...
  31. ncbi Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine
    Pietro Lampertico
    Department of Gastroenterology and Endocrinology, AM and A Migliavacca Center for Liver Disease, IRCCS Maggiore Hospital, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Italy
    Hepatology 42:1414-9. 2005
    ..In conclusion, to optimize antiviral treatment in HBeAg-negative patients selecting resistant strains to lamivudine, ADV should be added to lamivudine as soon as genotypic resistance is detected...
  32. ncbi Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C
    Alessio Aghemo
    AM and A Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS, Maggiore Hospital, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Expert Rev Anti Infect Ther 7:925-35. 2009
    ..Currently, two forms of pegylated IFN exist (alpha2a and alpha2b), which differ significantly in terms of pharmacokinetics and dynamics, is whether these peculiarities translate into different efficacy rates being still being debated...
  33. ncbi Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis
    Vincenzo Mazzaferro
    Department of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy
    Hepatology 44:1543-54. 2006
    ..3; 95% CI: 0.09-0.9; P = .04). In conclusion, IFN does not affect overall prevention of HCC recurrence after resection, but it may reduce late recurrence in HCV-pure patients receiving effective treatment...
  34. ncbi Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients
    Pietro Lampertico
    A M and A Migliavacca Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Gastroenterology 133:1445-51. 2007
    ..We assessed whether this risk could be overcome by adefovir-lamivudine combination therapy...
  35. ncbi Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection
    Alessio Aghemo
    A.M. Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 11:797-802. 2006
    ..Evaluation of liver fibrosis is important in the management of patients with genotype 3a hepatitis C, since it helps to predict response to IFN/RBV therapy...
  36. ncbi Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT
    M Vigano
    First Division of Gastroenterology, Department of Medicine, A M and A Migliavacca Center for Liver Disease, Fondazione IRCCS Ca Grande Ospedale Maggiore Policlinico, Universita di Milano, Milan, Italy
    Bone Marrow Transplant 46:125-31. 2011
    ..HBsAg-negative/anti-HBc-positive HSCT recipients with chronic onco-hematological disease carry a significant risk of HBsAg seroreversion and HBeAg-positive chronic hepatitis B, independently of serum levels of HBV DNA at transplantation...
  37. ncbi Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism
    A Bersano
    Department of Neurological Sciences Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 7 IRCCS, Via F Sforza 35, Universita degli Studi di Milano, Milano, Italy
    Eur J Intern Med 19:370-1. 2008
    ..IFN-based therapy has been associated with high rates (20%) of central nervous system side effects, but only a few case reports exist on extrapyramidal side effects...
  38. ncbi Transarterial embolization with microspheres in the treatment of monofocal HCC
    A Nicolini
    Division of Radiology, IRCCS Maggiore Hospital, Fondazione Policlinico, Mangiagalli e Regina Elena, and Centro A M and A Migliavacca, University of Milan, Milan, Italy
    Dig Liver Dis 41:143-9. 2009
    ..Transarterial embolization using one permanent embolic agent alone enhances tumour ischaemia and spares patients with hepatocellular carcinoma form toxic chemotherapeutic drugs...
  39. ncbi Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist
    G Ragni
    Infertility Unit, Department of Obstetrics and Gynaecology, University of Milan, Via Manfredo Fanti 6, 20122 Milan, Italy
    Hum Reprod 16:2258-62. 2001
    ..Forty-one infertile couples were recruited in this randomized clinical study...
  40. ncbi Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma
    Eugenia Biguzzi
    Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan and Department of Medicine and Medical Specialties, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    Thromb Res 120:289-93. 2007
    ..We postulated that soluble thrombomodulin and EPCR are plasmatic markers of progression to hepatocellular carcinoma (HCC) and prognostic indicators in cirrhotic patients...
  41. ncbi No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants
    Lucio Caccamo
    Dipartimento di Chirurgia Generale e dei Trapianti, U O Trapianto Fegato e Polmone, Ospedale Maggiore IRCCS di Milano, Istituto di Chirurgia Sperimentale, Cardiovascolare e dei Trapianti, Universita degli Studi di Milano, Italy
    Transpl Int 18:186-92. 2005
    ..Regardless of the presence of YMDD mutants, no hepatitis B recurrence was observed in our OLT recipients using pre-emptive lamivudine followed by continuous prophylaxis with lamivudine and HBIg...
  42. ncbi The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies
    Valentina Monti
    A.M. Et A. Migliavacca Center for Liver Disease, Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital Fondazione Policlinico, Mangiagalli, Regina Elena and University of Milan, Milan, Italy
    Antivir Ther 10:715-20. 2005
    ..CONCLUSIONS: LKM-1 antibodies rarely occur in patients with chronic hepatitis C and do not predict autoimmune hepatitis, interferon/ribavirin hyporesponsiveness or immune-related reactions to therapy...
  43. ncbi The use of bone-graft substitutes in large bone defects: any specific needs?
    G M Calori
    COR, Orthopaedic Institute, G Pini, University of Milan, Italy
    Injury 42:S56-63. 2011
    ..The purpose of this study was to evaluate the type of materials used and their efficacy for the treatment of large bone defects in traumatology and orthopaedic surgery...
  44. ncbi High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients
    F De Filippi
    Angela Maria e Antonio Migliavacca Center for Liver Disease, Department of Internal Medicine, IRCCS Maggiore Hospital, University of Milan, Italy
    Dig Liver Dis 33:477-9. 2001
    ..Low levels of hepatitis C virus-RNA found in hepatitis G virus carriers suggest an interaction between these two viruses in immunosuppressed patients...
  45. ncbi Treatment of chronic hepatitis C
    F De Filippi
    Division of Hepatology, Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    J Biol Regul Homeost Agents 17:133-7. 2003
    ..Extended treatment of virological non responders with pegylated interferons might slow down progression of hepatic fibrosis and prevent hepatocellular carcinoma...
  46. ncbi Interferon-alpha suppresses liver cell proliferation in patients with chronic hepatitis C virus infection
    M F Donato
    Department of Gastroenterology and Endocrinology, Division of Hepatology, A M and A Migliavacca Center for Liver Disease, IRCCS Ospedale Maggiore and FIRC Research Unit, University of Milan, Milan, Italy
    J Viral Hepat 12:499-506. 2005
    ..Although the strongest IFN effect was observed in virological responders, a reduction of proliferative activity was also seen in virological NRs...
  47. ncbi Proliferating cell nuclear antigen assessed by a computer-assisted image analysis system in patients with chronic viral hepatitis and cirrhosis
    M F Donato
    A M and A Migliavacca Liver Center and Italian Foundation for Research on Cancer, Unit of Liver Cancer, IRCCS Maggiore Hospital, University of Milan, Italy
    Dig Liver Dis 34:197-203. 2002
    ..Assessment of liver cell proliferation by immunodetection of proliferating cell nuclear antigen may predict regenerative potential and survival of liver and hepatocellular carcinoma risk in patients with chronic viral hepatitis...
  48. ncbi Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy
    Pietro Lampertico
    Division of Hepatology and Fondazione Italiana Ricerca Cancro Liver Cancer Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Maggiore Policlinico Hospital, University of Milan, Milan, Italy
    Hepatology 37:756-63. 2003
    ..71; 95% confidence interval, 1.17-2.50; P =.005). In conclusion, 24 months of treatment with interferon alfa 2b led to sustained disease suppression in a significant proportion of patients with HBeAg-negative chronic hepatitis B...
  49. ncbi Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B
    Mauro Vigano
    A M and A Migliavacca Center for Liver Disease, I Division of Gastroenterology Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Universita degli Studi di Milano, 20122 Milan, Italy
    Eur J Gastroenterol Hepatol 22:180-4. 2010
    ..Evaluation of liver stiffness (LS) using TE during acute hepatitis B may help to assess chronic hepatitis B patients with flares...
  50. ncbi The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients
    Angelo Sangiovanni
    A. M. e A. Migliavacca Center for Liver Diseases, Division of Gastroenterology, IRCCS Maggiore Hospital Fondazione Policlinico, Mangiagalli and Regina Elena, University of Milan, Milan, Italy
    Hepatology 43:1303-10. 2006
    ..In conclusion, hepatitis C-related cirrhosis is a slowly progressive disease that may be accelerated by other potential causes of liver disease. HCC was the first complication to develop and the dominant cause for increased mortality...
  51. ncbi The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin
    Mauro Vigano
    Angela Maria and Antonio Migliavacca Center for Liver Disease, First Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 14:789-96. 2009
    ..Those who are coinfected with hepatitis B virus (HBV), however, might suffer from HBV reactivation. The aim of this study was to assess HBV reactivation in HCV-coinfected inactive HBV carriers following IFN/RBV...
  52. ncbi Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C
    Alessio Aghemo
    A M Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Via F Sforza 35, 20122 Milan, Italy
    Nat Rev Gastroenterol Hepatol 7:485-94. 2010
    ..We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-alpha2a and PEG-IFN-alpha2b...
  53. ncbi Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis
    Mauro Vigano
    Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Antivir Ther 10:709-13. 2005
    ..The aim of the study was to assess the efficacy and safety of long-term lamivudine monotherapy in renal-transplant recipients with HBV-related cirrhosis...
  54. ncbi A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation
    Silvia Paggi
    Second Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    J Hepatol 49:564-71. 2008
    ..e. METAVIR F3,F4), to derive a prediction rule to confirm or exclude F3,F4...
  55. ncbi A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis
    M Iavarone
    Division of Hepatology, AM e A Migliavacca Center for Liver Disease, and FIRC Liver Cancer Unit, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    J Viral Hepat 10:423-6. 2003
    ..In conclusion, blood AFP mRNA is not a sensitive predictor of HCC in patients with compensated cirrhosis...
  56. ncbi Transient elastography in the assessment of liver fibrosis in adult thalassemia patients
    Mirella Fraquelli
    Second Division of Gastroenterology, Foundation IRCCS Cà Granda, Maggiore Policlinico Hospital and University of Milan, Milan, Italy
    Am J Hematol 85:564-8. 2010
    ..In beta-thalassemia patients, TE is a reliable tool for assessing liver fibrosis even if the influence of iron overload has to be clarified...
  57. ncbi High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C
    Maria Elisa Mancuso
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialities, University of Milan and IRCCS Maggiore Hospital, Mangiagalli, Italy
    Haematologica 91:1367-71. 2006
    ..016). INTERPRETATION AND CONCLUSIONS: These results show that combination therapy with Peg-IFNalpha2b plus ribavirin is highly efficacious in hemophiliacs with chronic hepatitis C...
  58. ncbi The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis
    Angelo Sangiovanni
    1st Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Via F Sforza 35, Milan, Italy
    Gut 59:638-44. 2010
    ..Contrast-enhanced ultrasound (CE-US), contrast CT scan and gadolinium dynamic MRI are recommended for the characterisation of liver nodules detected during surveillance of patients with cirrhosis with US...
  59. ncbi Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    Savino Bruno
    Liver Unit, Department of Medicine, AO Fatebenefratelli e Oftalmico, Milan, Italy
    Hepatology 45:579-87. 2007
    ..Irrespective of SVR achievement, all patients should continue surveillance because the risk of occurrence of HCC was not entirely avoided...
  60. ncbi Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy
    Elena Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Via Pace 9, 20122 Milan, Italy
    Blood 99:1089-91. 2002
    ..Thus, IFN and ribavirin combination therapy led to a sustained suppression of hepatitis in one third of hemophiliac patients resistant to conventional monotherapy...
  61. ncbi Hepatitis C virus and hepatocellular carcinoma
    M Colombo
    Division of Internal Medicine, Angela Maria e Antonio Migliavacca Center for Liver Disease, Milan, Italy
    Semin Liver Dis 19:263-9. 1999
    ..No reverse transcriptase activity has been found in infected livers, but there are data suggesting that HCV has oncogenic properties, because its interacts with cellular genes regulating cell growth and differentiation...
  62. ncbi Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group
    P M Mannucci
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Milan, Italy
    Ann Intern Med 120:1-7. 1994
    ..To determine whether an outbreak of hepatitis A virus (HAV) infection that occurred in 52 patients with hemophilia in Italy was acquired through infusion of contaminated factor VIII or through environmental enteric transmission...
  63. ncbi Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma
    M Colombo
    Division of Internal Medicine, FIRC University Unit for Liver Cancer, IRCCS Maggiore Hospital, University of Milan, Italy
    J Hepatol 31:25-30. 1999
    ..HCC could also be the consequence of HCV interacting with cellular genes that regulate cell growth and differentiation, independent of the effect of cirrhosis...
  64. ncbi A 24-month survey on root canal treatment performed by NiTi engine driven files and warm gutta-percha filling associated system
    M A Gagliani
    School of Dentistry, DMCO San Paolo, University of Milan, Milan, Italy
    Minerva Stomatol 53:543-54. 2004
    ..Aim of this paper is to evaluate, by a clinical longitudinal study, the type of sealing and the outcome of endodontic treatment, performed by new Profile and Thermafil technique, in teeth with or without periapical lesions...
  65. ncbi Bacterial communities and enzyme activities of PAHs polluted soils
    V Andreoni
    Dipartimento di Scienze e Tecnologie Alimentari e Microbiologiche, Universita degli Studi, Via Celoria 2, 20133 Milano, Italy
    Chemosphere 57:401-12. 2004
    ..can be consistent with the hypothesis that different phenanthrene-degrading strategies, cell surface properties, or the presence of xenobiotic-specific membrane carriers could play a role in the uptake/degradation of solid phenanthrene...
  66. ncbi HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues
    Pietro Lampertico
    1st Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Liver Int 29:130-2. 2009
    ..Long-term administration of NUCs, either as a monotherapy or as a sequential combination, inhibits HBV replication in most HBeAg-negative patients for at least 5 years, preventing clinical decompensation in cirrhotics...
  67. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens...
  68. ncbi A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma
    Raffaella Romeo
    A M Migliavacca Center, First Division of Gastroenterology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    Gastroenterology 136:1629-38. 2009
    ..We tracked the course of HDV infection in 299 patients over a mean period of 233 months...
  69. ncbi The natural history of hepatocellular carcinoma
    Raffaella Romeo
    Department of Internal Medicine, University of Milan, IRCCS Maggiore Hospital, Via Pace, 9, 20122 Milan, Italy
    Toxicology 181:39-42. 2002
    ..Much evidence indicates that these risk factors may interact with each other either as a group or as a single factor to modulate development of liver cancer...
  70. ncbi An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis
    Armando Tripodi
    Department of Internal Medicine and Medical Specialties, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy
    Gastroenterology 137:2105-11. 2009
    ..We investigated whether plasma from cirrhotic patients has an imbalance of pro- vs anti-coagulation factors...
  71. ncbi Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy
    Alessandro R Zanetti
    Istituto di Virologia, Universita degli Studi, Milano, Italy
    J Med Virol 70:27-30. 2003
    ..In addition, with the advent of additional treatment protocols, a rapid, reliable assay for changes in HCV load may permit more frequent patient assessment and tailoring of the therapeutic regimen...
  72. ncbi A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus
    Elena Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Via Pace 9, 20122 Milan, Italy
    Blood 102:78-82. 2003
    ....
  73. ncbi Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease
    Mirella Fraquelli
    Second Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Gut 56:968-73. 2007
    ..This study investigated these aspects...
  74. ncbi Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon
    Pietro Lampertico
    AM and A Migliavacca Center for Liver Disease, 1st Gastroenterology Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy
    Liver Int 31:90-4. 2011
    ....
  75. ncbi Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients
    Mauro Vigano
    Division of Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico Maggiore Hospital Fondazione Policlinico, Mangiagalli e Regina Elena, Centro A M and A Migliavacca, University of Milan, Milan, Italy
    Gastroenterology 133:835-42. 2007
    ..We assessed the development rates, morbidity, and influence on the evolutionary course of hepatitis C of CG...
  76. ncbi The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study
    Augusto B Federici
    Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Medical Specialties, IRCCS Maggiore Hospital, Mangiagalli, Regina Elena Foundation, University of Milan, Italy
    Haematologica 91:503-8. 2006
    ..The main objective of this study was to compare the prevalence and outcome of hepatitis C virus (HCV) infection in multi-transfused patients with VWD and in those with hemophilia A or B...
  77. ncbi Liver precancerous lesions and hepatocellular carcinoma: the histology report
    Massimo Roncalli
    Department of Pathology, University of Milan School of Medicine and Humanitas Clinical Institute, Rozzano, Milan, Italy
    Dig Liver Dis 43:S361-72. 2011
    ..The second part of the paper is devoted to the histopathology report of HCC on surgical specimens including explanted livers and on the differential diagnosis between HCC and liver metastasis...
  78. ncbi Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione IRCCS Ospedale Maggiore Policlinico Ca Granda IRCCS, Milan, Italy
    Hepatology 53:791-9. 2011
    ....
  79. ncbi Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H
    Agostino Cortelezzi
    Hematology 1 Bone Marrow Transplantation Unit and the IRCCS Fondazione Ospedale Maggiore, University of Milan, Via Francesco Sforza 35, 20122 Milan, Italy
    J Clin Virol 35:467-9. 2006
    ..During 20 months of anti-HBV therapy, ALT and HBV-DNA levels progressively declined and B-CLL was successfully kept under control by long-term alemtuzumab administration...
  80. ncbi Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study
    Maria Grazia Rumi
    AM Et A Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 12:1033-40. 2007
    ..The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators...
  81. ncbi Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough
    M G Rumi
    Division of Hepatology, Antonio e Angela Maria Migliavacca Center for Liver Disease and Fondazione Italiana Ricerca Cancro, Liver Cancer Unit, Ospedale Maggiore IRCCS and University of Milan, Italy
    J Viral Hepat 9:71-4. 2002
    ..Hence, extended surveillance of HCV carriers with consistently normal or minimally elevated ALT values is warranted as these patients are at risk of ALT flares and may develop progressive liver disease...
  82. ncbi Monotherapy vs. polytherapy in the treatment of forearm non-unions and bone defects
    G M Calori
    Reparative Orthopaedic Surgery Department, G Pini Institute, University of Milan, Milan, Italy Electronic address
    Injury 44:S63-9. 2013
    ....
  83. ncbi The natural history of hepatocellular carcinoma in Western countries
    M Colombo
    A M and A Migliavacca Center for Liver Diseases, FIRC Center for Liver Cancer, University of Milan
    Hepatogastroenterology 45:1221-5. 1998
    ....
  84. ncbi Updated definitions of healthy ranges for serum alanine aminotransferase levels
    Daniele Prati
    Centro Trasfusionale e di Immunologia dei Trapianti, Laboratorio di Epidemiologia, Divisione di Ematologia, Istituto di Statistica Medica e Biometria, Cattedra di Gastroenterologia, Milan, Italy
    Ann Intern Med 137:1-10. 2002
    ..Current standards for "normal" ALT level were defined by using populations that included persons with subclinical liver disease...
  85. ncbi Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls
    Pietro Invernizzi
    Department of Internal Medicine, Istituto Clinico Humanitas IRCCS, University of Milan, Milan, Italy
    Hepatology 48:1906-12. 2008
    ..We suggest that a large whole-genome approach is required to identify further genetic elements contributing to the loss of tolerance in this disease...
  86. ncbi Estimates of the incidence and prevalence of hepatocellular carcinoma in Italy in 2002 and projections for the years 2007 and 2012
    Cristina Bosetti
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Tumori 95:23-7. 2009
    ..Data on liver cancer incidence and prevalence in Italy are not available on a national and regional level...
  87. ncbi Risk factors for focal nodular hyperplasia of the liver: an Italian case-control study
    Astrid Scalori
    Divisione di Epatologia, Ospedale Maggiore IRCCS, , Milan, Italy
    Am J Gastroenterol 97:2371-3. 2002
    ..CONCLUSIONS: This study indicates that cigarette smoking is an indicator of elevated risk for FNH of the liver, whereas whole grain and, possibly, vegetable intake seems to be a favorable indicator...
  88. ncbi Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas
    Silvia Saccheri
    Institute of Radiology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    J Vasc Interv Radiol 13:995-9. 2002
    ..CONCLUSION: The rate of survival in patients with compensated cirrhosis and inoperable HCC did not appear to improve with use of TACE therapy...
  89. ncbi Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?
    E Galmozzi
    Centro A M e A Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Universita degli Studi di Milano, Italy
    Med Hypotheses 79:471-3. 2012
    ..In conclusion, our hypothesis provides a mechanistic explanation for the phenomenon of RBV enhancement in INFα-based therapy...
  90. ncbi Pain and ketoprofen: what is its role in clinical practice?
    P Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Reumatismo 62:172-88. 2010
    ....
  91. ncbi Randomised comparison of Burch colposuspension versus anterior colporrhaphy in women with stress urinary incontinence and anterior vaginal wall prolapse
    M Colombo
    Department of Obstetrics and Gynaecology, University of Milan, San Gerardo Hospital, Monza, Italy
    BJOG 107:544-51. 2000
    ..To compare the Burch colposuspension and the anterior colporrhaphy in women with both stress urinary incontinence and advanced anterior vaginal wall prolapse (cystocele)...
  92. ncbi GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gonadotrophin dosages
    G Ragni
    Infertility Unit, Department of Obstetrics and Gynaecology, University of Milan, Milan, Italy
    Hum Reprod 19:54-8. 2004
    ..In this study, we have compared two different protocols employing GnRH antagonists in order to determine the lower effective dose of gonadotrophins to use...
  93. ncbi Detection of genes for alkane and naphthalene catabolism in Rhodococcus sp. strain 1BN
    V Andreoni
    Dipartimento di Scienze e Tecnologie Alimentari e Microbiologiche, Universita degli Studi di Milano, Milan, Italy
    Environ Microbiol 2:572-7. 2000
    ..The oxidation of indene to cis-(1S,2R)-1,2-dihydroxyindan by toluene-induced cells allows to hypothesize that strain 1BN also carries a toluene dioxygenase-like system...
  94. ncbi Treatment of long bone non-unions with polytherapy: indications and clinical results
    G M Calori
    COR, Orthopaedic Institute, G Pini, University of Milan, Milan, Italy
    Injury 42:587-90. 2011
    ....
  95. ncbi The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma
    Luca Di Tommaso
    Department of Pathology, University of Milan School of Medicine and IRCCS Humanitas Clinical Institute, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    J Hepatol 50:746-54. 2009
    ....
  96. ncbi Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study
    Astrid Scalori
    Divisione di Epatologia, Ospedale Maggiore IRCCS, , , Milan, Italy
    Am J Obstet Gynecol 186:195-7. 2002
    ..CONCLUSIONS: This study confirms previous clinical observations, and provides a quantitative estimate of the association between use of oral contraceptives and focal nodular hyperplasia of the liver...
  97. ncbi Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants
    Alfredo Marzano
    Department of Gastroenterology, San Giovanni Battista Hospital, Turin, Italy
    Liver Transpl 11:532-8. 2005
    ....
  98. ncbi Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results
    Eugene Schiff
    Center for Liver Diseases, University of Miami, Miami, FL 33136, USA
    Liver Transpl 13:349-60. 2007
    ..In conclusion, adefovir dipivoxil is effective and safe in wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg...
  99. ncbi Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients
    Eugene R Schiff
    Center for Liver Diseases, University of Miami, Miami, FL 33136, USA
    Hepatology 38:1419-27. 2003
    ..In conclusion, 48 weeks of adefovir dipivoxil resulted in significant improvements in virologic, biochemical, and clinical parameters in CHB patients pre- and post-LT with lamivudine-resistant HBV...
  100. ncbi Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance
    Angelo Sangiovanni
    Department of Gastroenterology and Endocirnology, A.M. and A. Migliavacca Center for Liver Diseases, FIRC Unit on Liver Cancer, IRCSS Maggiore Hospital and University of Milan, Italy
    Gastroenterology 126:1005-14. 2004
    ..015). CONCLUSIONS: Cirrhotic patients developing a HCC during the last 5 years of surveillance survived longer than previously, as a consequence of improved management of the tumor and complications of cirrhosis...
  101. ncbi Recent progress and new trends in the treatment of hepatitis B
    Alfredo Alberti
    Department of Internal Medicine, University of Padua, Padua, Italy
    J Med Virol 67:458-62. 2002
    ..10%, P = 0.045), but not in Milan (7 vs. 10%, P = ns)...